While drug therapies, including bisphosphonates, anti-RANKL antibodies (denosumab), anti-sclerostin antibodies (romosozumab), and teriparatide, already exist to mitigate aging-related bone loss to some degree, a dearth of pharmacological therapeutic options is currently available to address issues related to dynapenia and sarcopenia with age (34, 35). This evidence concerns the gene SOST and sarcopenia.